Introduction
============

Acute bronchiolitis is the most common lower respiratory tract illness in infants and young children, and is usually the result of viral infection. Respiratory syncytial virus (RSV) is the most frequent infecting agent ([@b69-tcrm-4-895]). This disease is characterized by inflammation, edema, and necrosis of the small airway epithelium with associated bronchospasm and increased mucous production. Bronchiolitis is a seasonal illness with the highest incidence between December and March in the Northern Hemisphere. However, there is significant regional variability in the timing and duration of RSV seasons throughout the US ([@b45-tcrm-4-895]), and in tropical areas the virus is usually endemic and present in the community throughout the year.

Epidemiology
------------

Acute bronchiolitis is a far reaching illness. Virtually all children have been infected with RSV by the age of 2 years, and nearly half of those will experience two infections ([@b24-tcrm-4-895]). Of those infected, 40% will develop a lower respiratory tract infection (LRTI) ([@b8-tcrm-4-895]). It is estimated that each year, as many as 126,000 infants are hospitalized in the US due to bronchiolitis ([@b55-tcrm-4-895]). While this represents a large burden, the numbers outside of the US are staggering. Worldwide, as many as 1/200 infants are hospitalized annually for treatment of LRTI, with a mortality rate as high as 5% ([@b15-tcrm-4-895]). In the US, RSV-associated mortality has declined from 4500 deaths in 1985 ([@b56-tcrm-4-895]) to 390 deaths in 1999 ([@b37-tcrm-4-895]). The estimated annual cost of hospitalization for infants with bronchiolitis exceeds US \$700 million ([@b61-tcrm-4-895]).

Etiology
--------

Acute bronchiolitis is predominantly caused by viral infection, with RSV accounting for greater than 50% of cases. Other important viral causes include adenovirus, influenza virus, parainfluenza virus, human metapneumovirus, and rhinovirus. *Mycoplasma pneumoniae* may occasionally be associated with bronchiolitis.

RSV is extremely contagious, with a 98% attack rate for first-time infection during epidemics. This decreases to a 75% attack rate for second infections ([@b32-tcrm-4-895]). Transmission generally requires close contact, with exposure of the nasal mucosa or conjunctiva to infected secretions ([@b27-tcrm-4-895]). Thus, well implemented contact isolation precautions are effective in limiting spread of the infection.

Reinfection with RSV over an individual's lifetime is common; however, the first infection is generally the most severe and the most likely to involve the lower respiratory tract ([@b55-tcrm-4-895]). The second infection can also be quite severe, but after two RSV infections, the acquired immunity usually provides a significant reduction in the severity of a third and subsequent infections ([@b32-tcrm-4-895]). Prematurely born children with chronic lung disease remain at risk for severe RSV infections for the first two years of life, and many forms of immune deficit and congenital heart disease represent a risk factor independent of age ([@b40-tcrm-4-895]; [@b29-tcrm-4-895]; [@b7-tcrm-4-895]).

Pathophysiology
---------------

During the acute phase of bronchiolitis, the infecting virus precipitates an inflammatory response that results in edema, inflammatory cellular infiltration, and sloughing of the lower airway epithelium. This leads to bronchiolar plugging and hyperinflation, which is exacerbated by impaired ciliary clearance of mucous and cellular debris. After an early phase characterized by chemotaxis of polymorphonuclear leukocytes, the inflammatory infiltrates in infected airways become predominantly lymphomonocytic. In infants, the inflammation is generally limited to the small airways, sparing the alveoli ([@b58-tcrm-4-895]), whereas later in life the infection is usually limited to the upper respiratory tract and large airways. The inflammatory response to RSV appears to be amplified and sustained by the peripheral nervous system via complex neuro-immune interactions primed by the virus.

In immunocompetent hosts, the infection with RSV is cleared within two weeks, whereas immunocompromised hosts can harbor and spread the virus for several months. Despite being a relatively short, self-limiting infection, RSV bronchiolitis is followed by chronic respiratory sequelae in a large proportion of children, particularly as recurrent episodes of wheezing that frequently lead to a diagnosis of asthma during the first decade of life.

Clinical features
-----------------

The incubation period for RSV ranges from 2 to 8 days. Infants develop signs and symptoms of a mild upper respiratory tract infection within one week of exposure to an infected individual. This progresses to increased work of breathing, cough, wheezing, and irritability. The respiratory distress may range from mild to severe with nasal flaring, grunting, accessory muscle use and marked intercostal and subcostal retractions. Premature infants and newborns may present with decreased appetite, lethargy, and apnea after the upper respiratory tract infection prodrome.

Apnea is among the most common clinical manifestations of RSV infection in young infants, with an estimated incidence of 16%--25% ([@b51-tcrm-4-895]). A particularly high risk is associated with young age (\<3 months) and prematurity. Interestingly, apnea can be the presenting sign of this infection preceding the onset of wheezing and other lower respiratory symptoms. This clinical observation and data obtained in animal models suggest that RSV can trigger apnea in as early as the nasal phase of the infection, before spreading to the lower airways. Because of its ability to interfere with ventilatory control, RSV infection has also been suggested as a precipitating factor in cases of sudden infant death.

Supportive care
===============

The severity of bronchiolitis varies from mild to severe. Most infants endure a self-limited illness that can be treated in an outpatient setting, with close follow up to ensure that they have no respiratory distress, no supplemental oxygen requirement and remain well hydrated. Infants with moderate or severe disease characterized by poor feeding, tachypnea, nasal flaring or supplemental oxygen requirement should be admitted to the hospital for more aggressive management and monitoring. Regardless of the setting in which the patient is treated, the mainstay of therapy remains supportive care, which includes respiratory support and adequate fluid and nutrition management.

Children who are hypoxemic with oxygen saturations \<90% should receive warm, humidified oxygen ([@b8-tcrm-4-895]). Nasal obstruction is a common problem, and given that young infants are obligate nose breathers, may result in a significant increase in respiratory distress. Our experience has demonstrated that simple nasal toilet with saline drops and a suction bulb can significantly improve work of breathing and frequently abort the requirement for mechanical ventilatory support. Infants with hypoxemia refractory to supplemental oxygen, persistent respiratory distress or progressive respiratory failure usually require either non-invasive support with nasal continuous positive airway pressure (NCPAP) or endotracheal intubation.

Infants with bronchiolitis have decreased nutritional intake due to respiratory distress and tachypnea, which puts these patients at increased risk of aspiration and may therefore warrant the suspension of oral feeding. In addition, insensible losses are increased because of fever and elevated work of breathing. Adequate fluid intake and nutrition should be maintained with parenteral fluids or with placement of a nasogastric or orogastric feeding tube.

Pharmacological interventions
=============================

Bronchodilators
---------------

Bronchodilators are frequently tried in infants presenting with wheezing due to bronchiolitis because of its similarity to asthma. Their routine use is controversial. Despite many randomized, controlled trials (RCT), no consistent benefit has been demonstrated. It is probably sensible to give a brief trial of bronchodilators to patients with bronchiolitis while the effect is carefully monitored, but their use should be continued only if clinical improvement can be documented by objective endpoints.

### Albuterol

A number of small RCTs have evaluated the effectiveness of albuterol in the treatment of acute bronchiolitis, with conflicting results. A double-blind, placebo-controlled trial evaluated the efficacy of nebulized albuterol in the treatment of infants aged 0--24 months with wheezing ([@b54-tcrm-4-895]). Twenty-five infants were randomized to receive nebulized albuterol or saline placebo. The infants were assessed after each treatment for wheeze, retractions score, respiratory rate, heart rate, and pulse oximetry. In this study, the authors were able to demonstrate significant improvement in the wheeze and oxygenation scores of those infants that received albuterol, while no significant difference in the heart rate and respiratory rate were noted. These findings are supported by a Canadian double-blind, placebo-controlled trial that evaluated 40 infants between 6 weeks and 24 months of age with a first episode of wheezing and signs and symptoms of bronchiolitis ([@b52-tcrm-4-895]). Improvements were demonstrated in oxygenation and work of breathing after two doses of albuterol. A criticism of both of these studies is that the patients were not followed over time, and no effect was demonstrated in improved resolution of symptoms or in length of stay (LOS). In fact, several other studies have shown opposite results, suggesting that albuterol offers no consistent improvement in patients with bronchiolitis.

[@b22-tcrm-4-895] evaluated 88 infants with the first episode of wheezing in an emergency department setting. The subjects were randomized to receive two nebulized albuterol or nebulized placebo treatments 30 minutes apart or a single dose of oral albuterol or saline placebo. The investigators measured respiratory rate, heart rate, clinical scores, oxygen saturations and level of wakefulness. No significant difference was demonstrated among the four groups. [@b35-tcrm-4-895] demonstrated a short-term improvement in clinical scores 30 minutes after a single albuterol treatment; however no difference was demonstrated 60 minutes after the treatment. There was no difference between the two groups when oxygenation was compared.

Inpatient trials have also failed to demonstrate benefit in patients receiving nebulized albuterol. A small RCT evaluated 52 hospitalized infants with moderately severe acute viral bronchiolitis ([@b17-tcrm-4-895]). There was no improvement in oxygenation, time to meet discharge criteria, or length of stay. A 1992 meta-analysis of 8 clinical trials examined several outcomes ([@b20-tcrm-4-895]). The analysis was unable to demonstrate any impact on the hospitalization rate or respiratory rate. The authors did find a statistically significant, but clinically insignificant, improvement in oxygen saturation and heart rate. They concluded that evidence for the efficacy of β2-agonist therapy in bronchiolitis is lacking.

In summary, albuterol has not been shown to consistently reduce the duration or severity of illness or length of hospital stay, and so cannot be recommended for routine care of the patient with bronchiolitis. A carefully monitored trial in individual patients may be warranted, with discontinuation of therapy if no improvement is noted. Animal model studies suggesting that single-isomer preparations like levalbuterol may have a better anti-inflammatory effect than racemic albuterol in RSV-infected airways ([@b3-tcrm-4-895]) have yet to be confirmed in clinical trials.

### Racemic epinephrine

As with albuterol, the use of nebulized racemic epinephrine is controversial. No strong evidence exists to support its routine use; nevertheless, it is frequently used in wheezing infants with bronchiolitis. In a small, placebo-controlled, randomized trial, [@b36-tcrm-4-895] demonstrated an improvement in oxygen saturations at 30, 45 and 60 minutes after inhalation of nebulized epinephrine. However, the authors were unable to show that these responses improved the overall course. A small, non-controlled trial investigated the use of nebulized *l*-epinephrine in intubated infants with bronchiolitis, showing a significant reduction in airway resistance after treatment with nebulized epinephrine ([@b46-tcrm-4-895]). Despite this, there was no reduction in oxygen requirement.

More recently, a large RCT compared nebulized epinephrine with placebo in 194 infants hospitalized with bronchiolitis ([@b66-tcrm-4-895]). Patients were randomized to receive 3 doses of nebulized epinephrine or placebo, 4 hours apart. The authors evaluated length of stay, respiratory and heart rates, work of breathing, and length of oxygen therapy, and, again, found no significant reduction in the measured outcomes.

Several studies have compared the efficacy of nebulized albuterol against epinephrine. In one such study, [@b43-tcrm-4-895] compared nebulized epinephrine to albuterol in an emergency department setting. Of those patients who received nebulized epinephrine, 33% required hospital admission compared with 81% of the albuterol group. In this study, the authors conclude that nebulized epinephrine is more effective than albuterol in preventing hospitalization of infants with bronchiolitis. In another evaluation of the efficacy of nebulized epinephrine versus albuterol, [@b30-tcrm-4-895] conducted a meta-analysis of 14 available studies. Among outpatients, epinephrine was more effective than albuterol or placebo in the reduction of clinical score, improvement in oxygenation and respiratory rates, and overall improvement. The measured outcomes also indicated that epinephrine was more effective in the inpatient setting, with improvements in clinical score and respiratory rate. However, in 2004 a Cochrane report of the available data found a lack of evidence to support the use of epinephrine in the inpatient setting ([@b31-tcrm-4-895]). The report also determined that among outpatients, epinephrine may be more favorable than albuterol.

While no strong evidence exists to support the routine use of albuterol or epinephrine, the use of bronchodilators in select patients seems reasonable. When a bronchodilator trial is given, the available data supports the use of epinephrine over albuterol. If clinical improvement can be documented, then continued use is indicated. However, treatments should be discontinued if no improvement can be demonstrated. As epinephrine is typically not prescribed for use at home, albuterol may be a more appropriate choice for outpatient use.

Anticholinergic agents
----------------------

Anticholinergic agents such as ipratropium bromide have not been demonstrated to be effective in the treatment of bronchiolitis. Several studies have evaluated ipratropium alone and with albuterol. While minor improvements in oxygenation have been reported, there is no consistent, significant benefit to the overall clinical course or outcome ([@b67-tcrm-4-895]; [@b12-tcrm-4-895]; [@b53-tcrm-4-895]).

Corticosteroids
---------------

Corticosteroids are commonly used in the treatment of bronchiolitis as anti-inflammatory agents; their use may be as high as 60% of inpatient therapy ([@b8-tcrm-4-895]). Their appeal may be due to the similarities of bronchiolitis to asthma and to the role that corticosteroids play at many intracellular levels to reduce inflammation. In theory, corticosteroids should be of benefit in reducing the inflammatory response of the lower airways against viral infections, and for this reason they have been widely prescribed by physicians. But in reality, several studies and meta-analyses with corti-costeroids have failed to show any significant benefit in acute or long-term clinical outcomes of virus-induced wheezing, whether administered systemically or inhaled.

### Systemic corticosteroids

Bulow et al investigated the short and long term effects of systemic corticosteroids in infants admitted with RSV bronchiolitis ([@b9-tcrm-4-895]). One hundred and forty-seven hospitalized infants were randomized to receive 2 mg/kg/day prednisolone or placebo for 5 days. Outcomes measured included length of stay and use of adjunctive medications and supportive therapies while hospitalized, as well as at 1 month and 1 year follow up. This study found no evidence that prednisolone effected any of the outcome measures. Schuh et al evaluated 70 children under the age of 2 years presenting to the emergency department with moderate or severe acute bronchiolitis ([@b53-tcrm-4-895]). The patients were randomized to receive 1 mg/kg of oral dexamethasone vs placebo, and were evaluated hourly for 4 hours. Each group also received nebulized albuterol at 0, 30, 60, and 120 minutes. The authors demonstrated a greater rate of clinical improvement among the dexamethasone group, to such extent that there was a decrease in the admission rate (19% vs 44%) compared with the placebo group.

In a more recent study conducted in Thailand, [@b63-tcrm-4-895] evaluated 174 children hospitalized with acute bronchiolitis. The children were randomized to received 0.6 mg/kg of intramuscular dexamethasone or placebo. The authors evaluated the length of time to resolution of respiratory distress as the primary outcome. The duration of respiratory distress was decreased from 39 hours for the placebo group to 27.2 hours for the dexamethasone group, a difference of about 12 hours. The duration of oxygen was also reduced by 14.9 hours, and the hospital LOS was decreased by 13.4 hours.

Two meta-analyses are also available. [@b23-tcrm-4-895] evaluated 6 studies with a combined total of 347 subjects. The outcomes measured included LOS and impact on severity of symptoms. The authors reported statistically significant reductions in clinical symptom scores and a reduction in LOS of 0.43 hospital days/patient. These numbers are similar to those reported by Teeratakulpisarn et al. Although the reduction of hospitalization by half a day would not be clinically significant for the individual patient, the authors argue that approximately 51,000 hospital days could be saved annually by the routine use of corticosteroids.

Patel et al conducted a larger systematic review of 13 trials of glucocorticoid therapy in 1198 children with viral wheezing aged 0--30 months ([@b47-tcrm-4-895]). They found a similar decrease in LOS of 0.38 hospital days/patient, which however was not statistically significant. There was no difference in clinical scores, respiratory rate or oxygen saturation. For patients treated in the emergency department or clinic, there was no difference in admission rates. The authors do caution that significant heterogeneity of the included studies and results make the final analysis difficult to interpret with confidence, but concluded that this therapy lacks any significant clinical benefit compared to placebo and is not of benefit for this patient group.

In a more recent double blind, randomized trial, [@b13-tcrm-4-895] compared oral dexamethasone with placebo to study whether a single dose of oral dexamethasone (1 mg/kg) could reduce the need for hospitalization. Over a 3-year period, the authors enrolled 600 infants between the ages of 2 and 12 months presenting to the emergency department with first-time wheezing and a diagnosis of moderate-severe bronchiolitis. The primary outcome was hospital admission after 4 hours of emergency department observation. Secondary and later outcomes measured included: change in a respiratory assessment score, length of hospital admission, later medical visits or hospital admissions and adverse events. The authors found that a single dose of dexamethasone did not change the rate of hospital admission or the severity score of bronchiolitis after 4 hours. They also found no change in later outcomes.

### Inhaled corticosteroids

Several studies have evaluated inhaled corticosteroids in patients with bronchiolitis, but no consistent benefit has been demonstrated ([@b16-tcrm-4-895]; [@b11-tcrm-4-895]). A recent RCT compared 61 infants randomized to receive nebulized dexamethasone or saline; both groups also received nebulized epinephrine ([@b5-tcrm-4-895]). In this study, no statistically significant difference was noted in clinical score or oxygen saturation. There was, however, a significant reduction in LOS in the dexamethasone group, especially among the subgroup of prematurely born infants (6.5 ± 1.7 days vs 9.1 ± 1.9 days).

In a Cochrane review of 5 studies with a total of 374 infants, [@b6-tcrm-4-895] evaluated the use of inhaled corticosteroids to prevent post-bronchiolitic wheezing. This analysis demonstrated no reduction of wheezing, readmission rate, use of systemic corticosteroids or use of bronchodilators.

In general, young children without an atopic phenotype that wheeze in response to viral infections show a poor response to corticosteroids, and even children that will ultimately develop asthma are usually unresponsive to this therapy when they develop virus-induced wheezing during their first years of life. Another area of concern derives from safety considerations. In fact, severe RSV bronchiolitis typically occurs during the first year of life and coincides with a critical phase of rapid lung development. The safety of the therapeutic use of corticosteroids during this window, particularly at high doses and for prolonged periods, is virtually unknown and consequently no steroid has ever been approved by the US FDA for use in the first year of life.

We conclude that whether administered systemically or inhaled, corticosteroids should not be routinely used in the treatment of bronchiolitis. However, some specific patient populations may benefit from a trial of steroid therapy, particularly patients with family history (parental atopy or asthma) or medical history (atopic eczema) suggestive of atopic predisposition.

Ribavirin
---------

Ribavirin is a synthetic nucleoside analog that demonstrates good *in vitro* activity against RSV. Several factors make its routine use controversial: it is expensive, difficult to administer, and possibly a teratogen. Furthermore, the available studies are all small, have inconsistent quality, and have produced conflicting results.

Early studies were encouraging. In 1983, [@b28-tcrm-4-895] randomized 33 infants hospitalized with RSV to continuous aerosolized ribavirin for 3--6 days versus placebo. The riba-virin group demonstrated a greater improvement in severity score, lower respiratory tract signs, oxygen saturations and viral shedding compared to the placebo group. [@b50-tcrm-4-895] also demonstrated improved oxygenation and a greater rate of clinical improvement in patients receiving a short course of ribavirin, without evidence of adverse effects. [@b59-tcrm-4-895] conducted a double-blind, placebo-controlled trial of continuously aerosolized ribavirin in 28 mechanically ventilated infants with RSV infection, using nebulized sterile water as a control. This study reported a significant reduction in oxygen use and in the length of mechanical ventilation and hospitalization, especially among infants with no underlying illness, but these findings were criticized because bronchospasm associated with sterile water nebulization may artificially make ribavirin seem more effective ([@b44-tcrm-4-895]).

A subsequent, well-designed study evaluated ribavirin against nebulized saline in 42 mechanically ventilated patients with RSV bronchiolitis and respiratory failure ([@b26-tcrm-4-895]). The authors found no significant improvement in the length of oxygen therapy, aerosol therapy, mechanical ventilation, PICU stay, or hospital stay. These findings were supported by a similar study performed by [@b42-tcrm-4-895]. [@b62-tcrm-4-895] evaluated 26 infants randomized to receive ribavirin or placebo and found no difference in the rate of viral clearance between the two groups. In a longer outcome study, [@b18-tcrm-4-895] followed patients treated with ribavirin for RSV bronchiolitis over 1 year and was unable to demonstrate any short-term improvement in the clinical course or long-term reduction in the use of inhaled bronchodilators or steroids.

In the early 1990s, the AAP endorsed ribavirin use for RSV bronchiolitis. This stance has since changed and the current recommendation is that ribavirin should not be used routinely to treat children with bronchiolitis. It should, however, be considered to treat RSV infection in immuno-compromised hosts ([@b8-tcrm-4-895]).

Antibiotics
-----------

It is not uncommon for infants with bronchiolitis to receive antibiotic therapy. It is estimated that antibiotics are used in 34%--99% of uncomplicated bronchiolitis ([@b34-tcrm-4-895]; [@b65-tcrm-4-895]). This therapy is frequently started because the patient is febrile, but fever per se cannot reliably differentiate viral from bacterial infections ([@b49-tcrm-4-895]). In fact, the risk of bacterial superinfection in infants with bronchiolitis and fever is quite low (0.2%), even when the temperature is \>39 °C ([@b68-tcrm-4-895]). For intubated infants with severe bronchiolitis, the rate of secondary bacterial infection is much higher, and may be as high as 26% ([@b60-tcrm-4-895]).

When a secondary bacterial infection (SBI) is diagnosed, the most common sites are the urinary tract and the middle ear ([@b1-tcrm-4-895]; [@b48-tcrm-4-895]). In particular, infants with SBI are more likely to have a urinary tract infection than bacteremia or meningitis (12% vs 0.43%) ([@b48-tcrm-4-895]). Acute otitis media (AOM) is also seen as a complication of RSV infection (57%--67%), but its presence does not seem to influence the severity of fever, respiratory distress, or the overall clinical course of the disease ([@b57-tcrm-4-895]). In one series, evaluation of middle ear aspirates in children with bronchiolitis revealed RSV in 17 (71%) of 24 patients ([@b1-tcrm-4-895]). In addition, all patients with acute otitis media had bacterial pathogens isolated, the most common being *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. If present, AOM should be managed according to current AAP recommendations ([@b2-tcrm-4-895]; [@b8-tcrm-4-895]).

Several prospective RCTs have evaluated the clinical outcomes of infants who received antibiotics for the management of bronchiolitis. As early as 1966, a double blind RCT failed to demonstrate a benefit to treating bronchiolitis with antibiotics ([@b19-tcrm-4-895]). [@b21-tcrm-4-895] evaluated 136 children between the ages of 1 month and 6 years and found no difference in the course of the acute illness, fever relapse, or pulmonary complications in those patients with bronchiolitis who received antibiotics compared with those who did not ([@b21-tcrm-4-895]).

We conclude that antibiotics should be used in patients with bronchiolitis only when specific evidence of coexistent bacterial infection is present and confirmed bacterial infections should be managed no differently than in the absence of bronchiolitis.

Surfactant
----------

Beyond its role of decreasing surface tension in alveoli and bronchioles, thereby improving alveolar and small airway patency, surfactant has protein components (A and D) that bind viral and bacterial surface markers and facilitate their immune-mediated elimination ([@b64-tcrm-4-895]). In addition, surfactant protein D has been demonstrated to promote alveolar macrophage production of free radicals ([@b38-tcrm-4-895]). In acute bronchiolitis, there is decreased production of these surfactant proteins, which return to normal levels with the resolution of the illness ([@b14-tcrm-4-895]).

Administration of exogenous surfactant to infants with severe respiratory failure due to bronchiolitis seems promising. Several small RCTs have been conducted to evaluate this therapy, with encouraging results. A recent meta-analysis by [@b64-tcrm-4-895] included 3 studies with a total of 79 patients. The authors identify decreases in duration of mechanical ventilation and PICU stay. There also seem to be improvements in pulmonary mechanics and gas exchange. It is important to note that the available studies are small and underpowered, and that additional studies are required. However, exogenous surfactant therapy does appear to hold promise for use in patients with severe respiratory failure due to bronchiolitis.

Heliox
------

Medical helium for the treatment of upper airway obstruction and asthma was first described by Barach in the 1930s ([@b4-tcrm-4-895]). Heliox is a mixture of helium and oxygen in a 70:30 or 80:20 ratio that maintains greater laminar flow and less turbulence through constricted airways than does nitrogen-oxygen mixtures. This reduces work of breathing and improves ventilation in patients with lower respiratory tract disease. Heliox has been studied in the treatment of bronchiolitis by several investigators, although most of these studies are quite small. Some of the authors have shown small improvements in clinical scores and decreased tachypnea and work of breathing ([@b33-tcrm-4-895]; [@b41-tcrm-4-895]; [@b10-tcrm-4-895]).

[@b39-tcrm-4-895] evaluated rates of positive pressure ventilation in patients receiving heliox therapy vs standard nitrogen-oxygen air and found no difference between the two groups. When heliox therapy was evaluated in intubated children with bronchiolitis, Gross et al found no improvement in ventilation or oxygenation, regardless of the ratio of helium to oxygen employed (50:50, 60:40, or 70:30) ([@b25-tcrm-4-895]).

Heliox equipment is bulky and cumbersome and it can be problematic to administer. Furthermore, given that it is most effective at high helium to oxygen ratios, it is minimally effective in patients with higher oxygen requirements. In summary, the current evidence supporting heliox use for bronchiolitis is sparse, underpowered and conflicting, and therefore larger RCTs are required before it can be recommended for routine use.

Summary
=======

Bronchiolitis is a common lower respiratory tract infection in infants caused by viral agents, the most common of which is RSV. Despite numerous attempts to identify pharmacological therapies to improve the clinical course and outcomes of this disease, the most effective therapy remains supportive care. Careful attention should be focused on maintaining patency of the infant's airway with gentle nasal and pulmonary toilet. Supplemental humidified oxygen is frequently required to maintain oxygen saturations above 92%. Patients should be monitored to ensure adequate fluid and nutrition intake, which may require supplementation with naso-gastric feeds or intravenous fluids. Bronchodilators are not consistently effective, but may have some benefit in selected patients. If given to patients with bronchiolitis, their use should only be continued if objective measures demonstrate improvement in the patients oxygenation or work of breathing. Corticosteroids have not been shown to be effective and are not recommended for routine use. Ribavirin is not recommended for routine use in patients with bronchiolitis, although it may be of benefit in immunocompromised patients. Antibiotics should only be used in the presence of a confirmed bacterial infection. Surfactant and heliox therapies may be tried for the treatment of severe respiratory failure, although additional studies are needed before they can be recommended for routine use.
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